https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-2021-11
https://www.nasdaq.com/press-release/adc-therapeutics-announces-abstracts-to-be-presented-at-the-63rd-ash-annual-meeting
https://www.nasdaq.com/press-release/adc-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/adc-therapeutics-announces-validation-of-its-marketing-authorization-application-by
https://www.nasdaq.com/press-release/adc-therapeutics-to-host-third-quarter-2021-financial-results-conference-call-on
https://www.nasdaq.com/press-release/overland-adct-biopharma-announces-first-patient-dosed-in-china-with-zynlontar-in
https://www.nasdaq.com/press-release/adc-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-adct-901-in
https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-the-2021-cantor-virtual-global-healthcare
https://www.nasdaq.com/press-release/adc-therapeutics-receives-orphan-drug-designation-in-europe-for-zynlontar-2021-09-13
https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-morgan-stanleys-19th-annual-global-healthcare
https://www.nasdaq.com/press-release/adc-therapeutics-announces-medical-leadership-transition-2021-09-03
https://www.nasdaq.com/press-release/adc-therapeutics-enters-into-a-financing-agreement-with-healthcare-royalty-for-up-to-
https://www.nasdaq.com/press-release/adc-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/adc-therapeutics-to-host-second-quarter-2021-financial-results-conference-call-on
https://www.nasdaq.com/press-release/adc-therapeutics-announces-encouraging-interim-results-from-pivotal-phase-2-clinical
https://www.nasdaq.com/press-release/adc-therapeutics-presents-updated-zynlontatm-loncastuximab-tesirine-lpyl-clinical
https://www.nasdaq.com/press-release/adc-therapeutics-shareholders-approve-all-resolutions-at-the-annual-general-meeting
https://www.nasdaq.com/press-release/adc-therapeutics-announces-presentations-at-the-16th-annual-international-conference
https://www.nasdaq.com/press-release/adc-therapeutics-presents-updated-clinical-data-at-2021-asco-annual-meeting-2021-06
https://www.nasdaq.com/press-release/adc-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021-05-27
https://www.nasdaq.com/press-release/adc-therapeutics-announces-online-publication-of-camidanlumab-tesirine-phase-1
https://www.nasdaq.com/press-release/avid-bioservices-to-serve-as-commercial-manufacturer-for-adc-therapeutics-zynlontatm
https://www.nasdaq.com/press-release/adc-therapeutics-announces-presentations-at-the-2021-asco-annual-meeting-2021-05-19
https://www.nasdaq.com/press-release/adc-therapeutics-announces-receipt-of-%2450-million-second-tranche-of-convertible
https://www.nasdaq.com/press-release/adc-therapeutics-announces-online-publication-of-lotis-2-results-in-the-lancet
https://www.nasdaq.com/press-release/adc-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/adc-therapeutics-zynlontatm-loncastuximab-tesirine-lpyl-added-to-national
https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-may-investor-conferences-2021-05-04
https://www.nasdaq.com/press-release/adc-therapeutics-to-host-first-quarter-2021-financial-results-conference-call-on-may
https://www.nasdaq.com/press-release/adc-therapeutics-announces-fda-approval-of-zynlontatm-loncastuximab-tesirine-lpyl-in
https://www.nasdaq.com/press-release/overland-adct-biopharma-appoints-eric-koo-as-chief-executive-officer-2021-04-06
https://www.nasdaq.com/press-release/adc-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-and
https://www.nasdaq.com/press-release/adc-therapeutics-to-host-fourth-quarter-and-year-end-2020-financial-results
https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-cowen-41st-annual-health-care-conference-2021-02
https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-guggenheim-healthcare-talks-2021-oncology-day-2021
https://www.nasdaq.com/press-release/adc-therapeutics-completes-enrollment-in-pivotal-phase-2-clinical-trial-of
https://www.nasdaq.com/press-release/adc-therapeutics-initiates-expanded-access-program-for-loncastuximab-tesirine-in-the
https://www.nasdaq.com/press-release/adc-therapeutics-to-participate-in-sternir-virtual-corporate-access-event-2021-01-04
https://www.nasdaq.com/press-release/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs
https://www.nasdaq.com/press-release/adc-therapeutics-and-overland-pharmaceuticals-announce-formation-of-overland-adct
https://www.nasdaq.com/press-release/adc-therapeutics-announces-updated-clinical-data-on-lead-antibody-drug-conjugate
https://www.nasdaq.com/press-release/adc-therapeutics-to-host-conference-call-highlighting-data-from-its-next-generation
https://www.nasdaq.com/press-release/adc-therapeutics-announces-fda-accepts-biologics-license-application-and-grants
https://www.nasdaq.com/press-release/adc-therapeutics-reports-third-quarter-2020-financial-results-and-provides-recent
https://www.nasdaq.com/press-release/adc-therapeutics-to-present-at-the-stifel-2020-virtual-healthcare-conference-2020-11
https://www.nasdaq.com/press-release/adc-therapeutics-to-host-third-quarter-2020-financial-results-conference-call-on
https://www.nasdaq.com/press-release/adc-therapeutics-announces-eight-presentations-on-data-from-its-next-generation
https://www.nasdaq.com/press-release/adc-therapeutics-announces-first-patient-dosed-with-camidanlumab-tesirine-cami-in
https://www.nasdaq.com/press-release/genmab-and-adc-therapeutics-announce-amended-agreement-for-camidanlumab-tesirine-0
https://www.nasdaq.com/press-release/adc-therapeutics-announces-full-exercise-of-underwriters-option-to-purchase
https://www.nasdaq.com/press-release/new-ventures-funds-rebrands-as-scientia-ventures-2020-10-02
https://www.nasdaq.com/press-release/adc-therapeutics-announces-pricing-of-public-offering-2020-09-23
https://www.nasdaq.com/press-release/adc-therapeutics-announces-proposed-public-offering-2020-09-21
https://www.nasdaq.com/press-release/adc-therapeutics-submits-biologics-license-application-to-the-u.s.-food-and-drug
https://www.nasdaq.com/press-release/adc-therapeutics-announces-presentation-of-preliminary-findings-from-phase-1b
https://www.nasdaq.com/press-release/adc-therapeutics-announces-publication-highlighting-the-potential-of-camidanlumab
https://www.nasdaq.com/press-release/adc-therapeutics-gives-notice-of-partial-waiver-of-restrictions-pursuant-to-finra
https://www.nasdaq.com/press-release/adc-therapeutics-reports-second-quarter-2020-financial-results-and-provides-recent
https://www.nasdaq.com/press-release/adc-therapeutics-to-report-second-quarter-2020-financial-results-on-august-18-2020
https://www.nasdaq.com/press-release/adc-therapeutics-announces-first-patient-dosed-in-pivotal-phase-2-portion-of-lotis-3
